VectorCare Expands Tech Solutions to Power Mobile Home-Based Health Services

VectorCare | October 16, 2020

VectorCare Expands Tech Solutions to Power Mobile Home-Based Health Services

VectorCare, a Bay Area patient care logistics company, expands tech solutions to power mobile home-based health services. At the start of 2020, the healthcare industry saw the slow movement toward home-based care delivery transform into an urgent need. Yet most care providers are still using existing legacy technology to manage and deliver home healthcare services, making the coordination and tracking of remote care events extremely difficult.

Spotlight

Alberta Health Services provides health care and promotes wellness to 4.1 million Albertans every day. We are the skilled and dedicated professionals, support staff and physicians who come from numerous disciplines, from all walks of life, and from all corners of the world to provide the highest quality health care to all our patients. Our mission is to provide a patient-focused, quality health system that is accessible and sustainable for all Albertans.


Other News

How Remote Healthcare Administration May Spark a New Digital Norm

Managedhealthcareexecutive | April 15, 2020

As the nation continues to respond to the COVID-19 pandemic, Madaket wants to express its deep gratitude to the dedicated professionals on the front lines of patient care. These individuals and organizations are facing a herculean task: caring for others while putting their own health at risk. The burden of healthcare administration should be the least of the providers’ worries during this time. Yet, it is essential to keep on track, especially during a pandemic that causes increased care services. Many other healthcare professionals, like practice managers, billing staff, clearinghouses, and payers, are working tirelessly behind the scenes to support providers by performing credentialing, enrollment, and many more administrative duties. As third-party, outsourced administrative partners, clearinghouses, and RCM vendors, in particular, help providers ensure quality patient care remains the top priority, while they keep financial operations of practices and hospitals afloat. However, as workforces across the nation settle into remote operations to help flatten the coronavirus curve, clearinghouses and RCM vendors are likely going to see—if they haven’t already—interruptions to workflow. Many of these organizations are stuck navigating the bureaucratic and largely paper-based systems of data exchange between payers and providers. More than 80% of attachments shared between payers and providers are still traveling via snail mail or fax.

Read More

HEALTH TECHNOLOGY

Alkem Laboratories Ltd. to Launch State of the Art Technology for Diabetic Foot Ulcer Management

Alkem Laboratories Ltd. | January 13, 2022

Alkem Laboratories Ltd. (Alkem) hereby announces to launch a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval. This advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India. India currently has approximately 77 mn diabetes patients, the second highest in the world. A diabetic foot ulcer is one of the most significant and devastating complications of diabetes and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes. Approximately, 12-15% with diabetes suffer from DFU at least once in a lifetime. 5–24% of them will finally lead to limb amputation within 6–18 months after the first evaluation. The risk of foot ulceration and limb amputation increases with age and the duration of diabetes. Alkem has collaborated with Rokit Healthcare Inc. to commercialize the technology in India to help reduce amputation amongst DFU patients considering the negative impact of amputation on a patient's quality of life and the associated economic burden on the healthcare system. "In India, Diabetes is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year and compromise on their quality of life. To address the problem, Alkem has collaborated with Rokit Healthcare Inc., a global regenerative solutions company, to bring out novel solutions for the management of diabetic foot ulcers." Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd Adding further, Mr. Sandeep asserted, "Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives." About Alkem Laboratories Ltd Established in 1973 and headquartered in Mumbai, Alkemis a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The Company also has presence in more than 40 international markets, with the United States being its key focus market.

Read More

Six Telemedicine Concerns Plaguing Health Industry

Managedhealthcareexecutive | April 17, 2020

The use of telemedicine is growing rapidly among hospitals and physicians across the country. It promotes better patient care and has greater access to medical services. Telemedicine also promises to empower consumers with more information and control over their healthcare decisions than ever before. According to a report, 67% of patients mentioned using telemedicine has significantly increased their satisfaction with medical care. From presenting providers with a list of options for where and how they can treat their patients, telemedicine is the harbinger of new opportunities, but its implementation also carries certain concerns. Listed below are few telemedicine concerns that you’ll want to be proactive in identifying and resolving for successfully implementing telemedicine in your healthcare practice.

Read More

MEDICAL DEVICES

Medtronic announces regulatory approval and launch in Japan of Micra AV Transcatheter Pacing System

Medtronic | January 11, 2022

Medtronic plc, a global leader in healthcare technology,today announced it has received approval fromJapan'sMinistry of Health, Labor and Welfare for the sale and reimbursement of the Micra™ AV Transcatheter Pacing System (TPS), and the company will launch the product this month. This approval expands the number of patients inJapan– one of the largest markets in the world – who are eligible to receive the Micra TPS, the world's smallest pacemaker. The Micra AV is indicated for the treatment of patients with AV block, a condition in which the electrical signals between the chambers of the heart (the atria and the ventricle) are impaired. The Micra TPS is the first-ever leadless pacemaker; its first version (the Micra VR) was approved inJapanin 2017 for patients who only require single-chamber pacing. "Pacemakers have made significant progress over their approximately 60-year history, including miniaturization, improvements in pacing technology, MRI compatibility, and remote monitoring," explainedKyoko Soejima, professor of cardiovascular internal medicine at Kyorin University Hospital and a member of the Micra TPS Global Clinical Trial steering committee. "The first Micra system transformed the concept of pacemakers by eliminating surgical pockets and leads, and Micra AV promises to deliver the benefits of leadless pacing to a larger number of patients because ventricular pacing can be performed synchronously with the atrium." Historically, patients with AV block have been treated with traditional dual-chamber pacemakers which are implanted in the upper chest, under the skin below the collar bone, and connected to the heart using thin wires called "leads." Identical in size and shape to the original Micra TPS, Micra AV has several additional algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium, providing "AV synchronous" pacing therapy to patients with AV block. The Micra AV approval is based on data from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study, which evaluated the safety and effectiveness of accelerometer-based atrial sensing algorithms. The study evaluated the ability of the Micra's internal sensor to monitor and detect atrial contractions and enable coordinated pacing between the atrium and ventricle, thereby providing AV synchrony. "Since introducing the first battery-powered external pacemaker in 1957 to the innovative Micra leadless pacemaker portfolio, Medtronic continues to pioneer pacing innovations for physicians and their patients." Rob Kowal, M.D., Ph.D., chief medical officer of the Cardiac Rhythm Management business at Medtronic About the Micra Transcatheter Pacing Systems (TPS) The Micra TPS received CE Mark inApril 2015and U.S. FDA approval in 2016. Comparable in size to a large vitamin, Micra is less than one-tenth the size of traditional pacemakers yet delivers advanced pacing technology to patients via a minimally invasive approach. During the implant procedure, the device is attached to the heart with small tines and delivers electrical impulses that pace the heart through an electrode at the end of the device. Unlike traditional pacemakers, Micra does not require leads or a surgical "pocket" under the skin, so potential sources of complications related to leads and pockets are reduced, and there is no visible sign of the device. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered inDublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.

Read More

Spotlight

Alberta Health Services provides health care and promotes wellness to 4.1 million Albertans every day. We are the skilled and dedicated professionals, support staff and physicians who come from numerous disciplines, from all walks of life, and from all corners of the world to provide the highest quality health care to all our patients. Our mission is to provide a patient-focused, quality health system that is accessible and sustainable for all Albertans.

Resources